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Epidemiology
AbstrAct
Background Polymyalgia rheumatica (PMr) and giant 
cell arteritis (gca) are almost always treated with 
glucocorticoids (gcs), but long-term gc use is associated 
with diabetes mellitus (DM). the absolute incidence of this 
complication in this patient group remains unclear.
Objective to quantify the absolute risk of gc-induced DM 
in PMr and gca from published literature.
Methods We identified literature from inception to 
February 2017 reporting diabetes following exposure to 
oral gc in patients with PMr and/or gca without pre-
existing diabetes. a random-effects meta-analysis was 
performed to summarise the findings.
Results 25 eligible publications were identified. in studies 
of patients with gca, mean cumulative gc dose was 
almost 1.5 times higher than in studies of PMr (8.2 g 
vs 5.6 g), with slightly longer treatment duration and 
longer duration of follow-up (6.4 years vs 4.4 years). the 
incidence proportion (cumulative incidence) of patients 
who developed new-onset DM was 6% (95% ci 3% to 9%) 
for PMr and 13% (95% ci 9% to 17%) for gca. Based on 
UK data on incidence rate of DM in the general population, 
the expected background incidence rate of DM over 4.4 
years in patients with PMr and 6.4 years in patients 
with gca (follow-up duration) would be 4.8% and 7.0%, 
respectively. Heterogeneity between studies was high 
(i2=79.1%), as there were differences in study designs, 
patient population, geographical locations and treatment. 
little information on predictors of DM was found.
Conclusion Our meta-analysis produced plausible 
estimates of DM incidence in patients with PMr and gca, 
but there is insufficient published data to allow precise 
quantification of DM risk.
InTROduCTIOn
Polymyalgia rheumatica (PMR) is a gluco-
corticoid (GC)-responsive condition causing 
bilateral shoulder and pelvic girdle pain and 
stiffness in older people.1 PMR is one of the 
most common reasons for long-term GC 
treatment in the community.2–4 Giant cell 
arteritis (GCA) is also treated with long-term 
GCs, but at higher doses,5 and is the most 
common primary systemic vasculitis affecting 
individuals aged over 50 years. The UK inci-
dence of PMR is 8.4/10 000 person-years2 
and of GCA is 2.2/10 000 person-years.6 Both 
diseases have a female:male ratio of 2–3:11 5 
and similar age distribution, with incidence 
peaking in the eighth decade of life. This age 
group is particularly vulnerable to the adverse 
effects of GC, which relate both to dose and 
duration of therapy7; the majority of patients 
with PMR and GCA experience GC-associ-
ated adverse effects.8 The most worrisome of 
these for both patients and rheumatologists is 
Key messages
What is already known about this subject?
 ► Polymyalgia rheumatica (PMr) and giant cell 
arteritis (gca) are inflammatory disorders of 
the elderly, with glucocorticoids (gc) being the 
treatment of choice.
 ► chronic use of gc is associated with diabetes 
mellitus (DM), though the absolute risk of 
developing DM is unclear.
What does this study add?
 ► Our meta-regression suggests that the incidence 
proportion (cumulative incidence) of patients who 
developed new-onset DM was 6% (95% ci 3% 
to 9%) for PMr and 13% (95% ci 9% to 17%) for 
gca, which is plausible, though there is insufficient 
published data to allow precise quantification of 
DM risk.
How might this impact on clinical practice?
 ► Findings from this study underline the importance 
of screening for gc-induced DM in patients with 
gca/PMr in clinical practice and can also help 
inform dietary and lifestyle advice in patients taking 
gcs for gca or PMr.
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diabetes mellitus (DM).9 Long-standing DM is associated 
with complications such as chronic kidney disease, retin-
opathy, diabetic neuropathy and so on, which often lead 
to a decline in quality of life, as well as marked shortening 
of life expectancy. This is also significant from a health 
economic perspective as it incurs significant additional 
healthcare utilisation. Despite the importance of this for 
patients, physicians and payers, there is currently minimal 
information on what the absolute risk of diabetes is in 
this particular patient group and which patients are at 
the greatest risk of developing new-onset diabetes while 
taking GC for PMR or GCA. Quantification of the costs 
and burdens of GC adverse effects allows assessment 
of the benefit of new therapies intended to reduce GC 
exposure while maintaining disease control.10 
It is recommended that clinicians take comorbidity and 
prognostic risk factors into account when making treat-
ment decisions,1 5 but as regards for risk of DM, clinicians 
must rely on indirect evidence extrapolated from other 
populations, such that the strength of the evidence for 
this would need to be downgraded for clinical guide-
lines.1 5 We aimed to collate published literature that 
could help to answer this question.
MeTHOds
search strategy
We searched for published studies or conference abstracts 
indexed in PubMed, Ovid (Medline and Embase), Web 
of Science, Cochrane Library and Cumulative Index of 
Nursing and Allied Health Literature from inception to 
February 2017. The search included terms for patients 
with PMR and/or GCA who were prescribed oral GC 
therapy, as well as diabetes-related terms as some indi-
viduals eventually developed diabetes. The full search 
strategy is available in online supplementary appendix 
1. We also manually screened reference lists of selected 
retrieved articles to identify further papers that may 
have been missed in the database search. We made every 
effort to include all available studies and conference 
abstracts (regardless of publication year), which included 
contacting the first authors by email if necessary. The 
selection process of identifying relevant studies is shown 
in figure 1.
eligibility criteria
We identified original research articles, conference 
abstracts and grey literature that reported diabetes 
Figure 1 Flow chart of the selection process of studies. CINAHL, Cumulative Index of Nursing and Allied Health Literature.
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following exposure to oral GC therapy. The populations 
of interest were patients with a diagnosis of PMR and/
or GCA with no pre-existing diabetes. We assume that, if 
not otherwise stated, all patients with PMR or GCA were 
treated with GCs. We included all randomised controlled 
trials, cohort studies, cross-sectional studies and case–
control studies. Case series and case reports were 
excluded. There was no language restriction. Non-Eng-
lish articles were translated with the help of Google 
Translate and colleagues who were native speakers of the 
respective languages.
study selection
Two investigators (LYHL and EH) independently carried 
out the initial screening of search results by title and 
abstract, using the abstract screener software ‘Abstrackr’11 
and Endnote X7.4 (1988–2015 Thomson Reuters). Study 
eligibility was determined independently, and any disa-
greements were resolved by consensus with the third 
investigator (SLM).
data extraction
Data were extracted independently by LYHL and EH using 
a standardised data collection Microsoft Access database. 
Any discrepancies in data extraction were resolved by 
consensus. For articles containing more than one study 
group, we included the ‘GC-only’ arm and excluded the 
groups where there was another study drug in addition to 
GCs. We also performed a sensitivity analysis by incorpo-
rating all the study groups into our analysis. Information 
extracted included journal information, publication year, 
year of enrolment, study design, patient demographics 
(age, sex, body mass index, weight, height, medical 
history, family history, glucose level and HbA1c), number 
of patients recruited, number of patients with DM, defini-
tion of DM, GC indication, treatment dose and duration 
and duration of follow-up. Patient populations were clas-
sified as ‘PMR’ or ‘GCA’ based on their primary diagnosis 
as determined by the authors. We only included studies 
where the authors identified ‘new-onset diabetes’ asso-
ciated with GC use. We excluded any prediabetic states 
Table 1 Studies included in the meta-analysis
First author, publication year Country Population Study design
Start of study 
enrolment
von Knorring, 197936 Finland PMR Observational 1967
Godeau, 198237 France GCA Observational 1966
Chuang, 198238 USA PMR Observational 1970
Behn, 198339 UK PMR Observational 1968
Gouet, 198540 France GCA Observational 1970
Andersson, 198641 Sweden GCA Observational 1968
Delecoeuillerie, 198842 France GCA Observational 1976
Nesher, 199443 Israel GCA Observational 1978
Gabriel, 199744 USA PMR Observational 1970
Jover, 20018 Spain GCA RCT 1993
Proven, 200345 USA GCA Observational 1950
Hutchings, 200746 UK PMR Observational 2001
Salvarani, 200747 Italy PMR RCT 2003
Cimmino, 200848 Italy PMR RCT 1998
Schmidt, 200849 Germany GCA Observational 1997
Dasgupta, 200950 UK PMR Observational 2001
Khalifa, 200951 Tunisia GCA Observational 1986
Martinez-Lado, 201152 Spain GCA Observational 1992
Mazzantini, 201253 Italy PMR Observational 1997
Dunstan, 201454 Australia GCA Observational 1991
Alba, 201455 Spain GCA Observational 1995
Seror, 201456 France GCA RCT 2006
Muller, 201657 France GCA Observational 2002
Carbonella, 201658 Italy GCA Observational NA
Faurschou, 201731 Denmark GCA Observational 1997
GCA, giant cell arteritis; PMR, Polymyalgia rheumatica; RCT, randomised controlled trial. 
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(eg, increased fasting glucose and glucose intolerance) 
or exacerbation of pre-existing diabetes (eg, worsened 
diabetes and addition of insulin).
statistical analysis
The incidence proportion (cumulative incidence) of 
new DM cases was modelled using binomial regression 
where the outcome variable was the number of DM cases 
given the number of GC-treated patients. The candidate 
explanatory variables included were: mean age, propor-
tion of females, year of enrolment, diagnosis (PMR or 
GCA), cumulative dose and treatment duration. Variables 
were clinically prioritised for inclusion in the multivar-
iable modelling rather than taking a purely data-driven 
approach. Results were presented as OR and 95% CI. We 
carried out a meta-analysis using a random-effects model. 
Statistical analysis was done with R (V.3.3.1.).12 The 
Meta-analysis of Observational Studies in Epidemiology 
reporting guidelines13 was used as a checklist (online 
supplementary appendix 2) to ensure proper evaluation 
of quality and completeness, and the risk of bias for both 
observational studies and RCTs were assessed using the 
Cochrane Collaboration tool for assessing risk of bias.14 
The risk of bias assessment was done independently by 
authors and discrepancies were resolved by consensus.
ResulTs
Our systematic literature search identified 25 eligible 
publications consisting of 24 journal articles and 1 confer-
ence abstract. Of the final 25 studies, 21 were cohort 
studies and 4 were RCTs; 9 studies reported on predomi-
nantly PMR patients, while 16 studies reported predomi-
nantly GCA patients. Nine of the 16 studies we classified 
as GCA studies included some patients with polymyalgic 
symptoms. Four of the nine studies we classified as PMR 
studies included some patients who also had been diag-
nosed with GCA, but we decided to classify them as PMR 
studies because that was the primary diagnosis as deter-
mined by the authors.
Most of the studies were conducted in Europe (n=20), 
followed by USA (n=3), Australia (n=1) and Tunisia 
(n=1). A total of 19 studies started enrolment before 
the year 2000, the earliest commencing study enrolment 
in 1950. Details of the individual studies are shown in 
table 1.
The weighted mean age across the studies reviewed was 
71.6 years for PMR and 74.9 years for GCA, with approx-
imately two-thirds being female (table 2). Cumulative 
dose in the GCA group was higher than the PMR group, 
with longer treatment duration and follow-up as well.
Of the 25 studies, prednisone was used in 15 studies 
and prednisolone in 8 studies. Patients from one study 
were on 6-methylprednisolone, and one study did not 
specify the type of GC used.
The incidence proportion of patients with PMR who 
developed new-onset DM was 6% (95% CI 3% to 9%) 
and the incidence proportion of patients with GCA who 
developed new-onset DM was 13% (95% CI 9% to 17%) 
(figure 2). Six studies reported a newly diagnosed DM 
during follow-up, 1 during GC treatment and 18 studies 
did not specify when DM was diagnosed.
We also performed a sensitivity analysis by incorpo-
rating all the study groups into our analysis, of which it 
did not alter our results (data not shown).
We combined both statistical and clinical consider-
ations to select the most parsimonious clinically relevant 
model to explore the predictors of GC-induced DM. In 
our study, the risk of developing new-onset DM among 
patients with GCA was doubled the risk of patients with 
PMR (online supplementary appendix 3), which was 
also reflected in our meta-regression results (13% vs 6%, 
respectively).
Most RCT studies scored a low risk in most domains; in 
some cases, however, we were unable to assess the risk of 
bias due to insufficient information (table 3).
The overall risk of bias was high for many of the 
observational studies, especially for domains relating 
to the outcome and prognostic variables (table 4). DM 
was not precisely defined in the studies, and there was 
a lack of uniformity on how it was measured. Of the 
25 studies, only six included an a priori definition of 
DM. Even with these six studies, various measurement 
methods were used, ranging from random blood sugar 
estimations to fasting plasma glucose levels to use of 
pharmacological interventions such as oral antidiabetic 
drugs and insulin. In 13 articles (52%), adjustment 
and assessment of prognostic variables were not well 
accounted for.
Table 2 Summary characteristics of individuals with PMR 
and/or GCA
Total (n=3743) PMR (n=920)
GCA 
(n=2823)
Demographics
  Age at 
baseline*, 
years
74.1 (3.6) 71.6 (3.1) 74.9 (3.7)
  % Female 67.8 (10.6) 71.0 (10.7) 66.7 (10.5)
Glucocorticoids 
use
  Cumulative 
dose, g
7.6 (4.2) 5.6 (3.3) 8.2 (4.5)
  Duration 
of GC use, 
years
2.4 (1.5) 2.1 (1.2) 2.5 (1.6)
Follow-up
  Duration, 
years
5.9 (4.1) 4.4 (3.3) 6.4 (4.4)
All data are presented as a weighted mean (SD) across studies.
*Age at diagnosis (n=11), age at study inclusion (n=3), age 
unspecified in study (n=11).
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dIsCussIOn
There is overwhelming epidemiological and pathophys-
iological evidence that GC therapy may cause DM.15–19 
Our aim was to estimate the effect size in this particular 
population for the purpose of informing clinical 
decisions about care of patients with PMR/GCA and 
health economic analyses about the cost-effectiveness 
of new therapies for PMR/GCA. In our meta-analysis of 
published literature, the estimated incidence propor-
tion (cumulative incidence) of new-onset diabetes was 
Table 3 Risk of bias of randomised controlled trials
Random 
sequence 
generation
(selection bias)
Allocation 
concealment 
(selection bias)
Blinding of 
participants 
and personnel 
(performance 
bias)
Blinding of 
outcome 
assessment
(detection bias)
Incomplete 
outcome data 
(attrition bias)
Selective 
reporting 
(reporting bias)
Jover et al8 L U L U L L
Salvarani et al47 L L L L L U
Cimmino et al48 L U L L L U
Seror et al56 L L L L H U
H, high risk of bias; L, lower risk of bias; U, unclear risk of bias.
Figure 2 Proportion of PMR and GCA patients who developed new-onset DM after GC use. GCA, giant cell arteritis; PMR, 
polymyalgia rheumatica.
A
U
TH
O
R
 P
R
O
O
F
6 lai lYH, et al. RMD Open 2018;0:e000521. doi:10.1136/rmdopen-2017-000521
RMD Open
6% (95% CI 3% to 9%) for patients with PMR and 13% 
(95% CI 9% to 17%) for patients with GCA. These figures 
are plausible: they are slightly higher than current UK 
population rates for patients of this age and sex, of which 
the expected background incidence rate of DM over 
4.4 years in patients with PMR and 6.4 years in patients 
with GCA (follow-up duration) would be 4.8% and 7.0%, 
respectively.20 It should also be noted that many of the 
studies we reviewed were conducted at a time when popu-
lation incidence of DM was lower than it is now.20 In addi-
tion, a few studies,21–25 including a recent meta-analysis,26 
have shown that patients with GCA had a lower prev-
alence of DM at the time of GCA diagnosis compared 
with age-matched and sex-matched controls, which 
may suggest that the magnitude of GC-induced DM to 
be greater than expected. Two observational studies27 28 
found no difference in pre-existing DM between patients 
with GCA and their comparison patients, while another 
two studies29 30 reported a higher prevalence of DM in the 
GCA cohort.
A very recent Danish study31 reported that the inci-
dence risk ratio of new-onset DM was 7.0 (95% CI 5.2 
to 9.3) in the GCA cohort during the first year of obser-
vation when compared with the general population. 
Beyond the first year, they reported that the incidence 
rates for DM were not significantly increased. In another 
large observational study of 5011 patients with GCA, the 
incidence risk ratios of DM was 1.4 (95% CI 1.2 to 1.7) 
as compared with matched non-GCA patients.32 The 
median time for the occurrence of DM in the GCA group 
was 1 year, which supports the hypothesis that the risk of 
developing GC-induced DM may be highest within the 
first year of GC use. Other datasets emphasise cumulative 
dose: a very recently published US study reported that 
the risk for new-onset DM rose 5% with each 1000 mg of 
GC exposure in patients with GCA.33
Heterogeneity in study design was high; the study 
populations were diverse in terms of disease manifesta-
tion, situated at different geographical locations and 
were also subjected to different treatment strategies. In 
Table 4 Risk of bias of observational studies
Similar 
population
Assessment 
of exposure
Outcome not 
present at 
start of study
Adjustment 
of 
prognostic 
variables
Assessment 
of 
prognostic 
variables
Assessment 
of outcome
Adequate 
follow-up
von Knorring et al36 ++ + − −− −− − +
Chuang et al38 + ++ −− −− ++ −− +
Godeau et al37 − − −− −− −− −− −− 
Behn et al39 ++ ++ −− −− −− −− +
Gouet et al40 + + −− −− −− −− +
Andersson et al41 ++ ++ −− −− −− −− +
Delecoeuillerie et al42 ++ ++ −− −− −− −− +
Nesher et al43 ++ ++ −− − + −− +
Gabriel et al44 ++ ++ + + ++ ++ +
Proven et al45 ++ ++ + + ++ ++ +
Hutchings et al46 ++ ++ −− + + + −− 
Schmidt et al49 ++ ++ − + + −− − 
Dasgupta et al50 + − − −− −− −− +
Khalifa et al51 + + −− −− −− −− −− 
Martinez-Lado et al52 + ++ −− + ++ −− +
Mazzantini et al53 ++ ++ ++ + + ++ +
Dunstan et al54 ++ ++ + ++ + −− +
Alba et al55 ++ ++ + ++ −− + +
Carbonella et al58 + −− −− −− −− −− − 
Farschou et al31 ++ ++ + − ++ ++ ++
Muller et al57 ++ + −− −− + −− − 
Question 1: was selection of exposed and non-exposed cohorts drawn from the same population? Question 2: can we be confident in the 
assessment of exposure? Question 3: can we be confident that the outcome of interest was not present at start of study? Question 4: did 
the study match exposed and unexposed for all variables that are associated with outcome of interest or did the statistical analysis adjust for 
these prognostic variables? Question 5: can we be confident in the assessment of the presence or absence of prognostic factors? Question 
6: can we be confident in the assessment of outcome? Question 7: was the follow up of cohorts adequate? 
++, definitely yes (low risk of bias); +, probably yes; −, probably no; −−, definitely no (high risk of bias).
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addition, the studies included in this meta-analysis were 
done over a span of 40 years, during which time clinical 
practice is likely to have changed. This heterogeneity was 
also reflected in high statistical heterogeneity identified 
by our meta-analysis as assessed by the I2 and tau-squared, 
the DerSimonian-Laird estimate derived from a random 
effects model. One particular difficulty was the lack of 
clarity and consistency regarding the definition of DM in 
the studies identified. It was also difficult to identify the 
onset of DM as most of the studies (72%) did not specify 
whether DM developed during GC treatment or during 
the follow-up period.
Since most of the studies reviewed did not have the 
primary aim of quantifying DM risk in PMR/GCA, the 
detail available in published reports was limited. For 
example, summary measures such as mean starting dose, 
mean treatment duration and mean cumulative dose 
cannot fully capture the pattern of GC dosing used for 
PMR/GCA, where the highest GC burden occurs during 
the first 3 months.1 5 34
Because GCs are the mainstay of treatment for PMR 
and GCA, it was not possible to disentangle the effect 
of the disease from the effect of the treatment. It is 
however known that systemic inflammation itself can also 
induce a state of insulin resistance,7 35 so it is plausible 
that the inflammatory disease itself (PMR or GCA) could 
have contributed to the risk of new-onset DM. In addi-
tion, some medications commonly prescribed to elderly 
patients may contribute to the risk of DM (eg, thiazide 
diuretics, beta-blockers, niacins and statins). These were 
not reported by the studies identified, as their primary 
focus was not on DM.
Confounding by indication could not be excluded. For 
example, for the observational studies, clinicians may 
have been less willing to prescribe higher GC doses to 
control disease activity in obese patients at high risk of 
DM. We were also unable to exclude spurious association 
due to a possible detection/screening bias; longitudi-
nally collected individual patient data would have been 
informative in this regard.
The overall risk of bias was high for many of the obser-
vational studies, especially for domains relating to the 
outcome and prognostic variables. Therefore, results 
should be interpreted with caution.
It is possible that studies that did not look for diag-
noses of DM or found no cases of new onset DM would 
not have mentioned diabetes and therefore have been 
excluded from our search. This could have led to an over-
estimate in the incidence of DM. Since DM has long been 
a concern with GC therapy, however, this is unlikely.
Our attempt to identify predictors of DM in this 
meta-analysis is more exploratory in nature as there 
are some limitations in the multivariable modelling. 
With this limited dataset and large number of potential 
explanatory variables, there is a risk of overfitting and 
may limit generalisability of this model. Other limitations 
of the model include the assumption that there is a linear 
relationship between variables, but it is also possible that 
collinearity may exist among some of the predictor vari-
ables. We excluded follow-up duration in our analysis 
because there is a high possibility that follow-up duration 
was confounded with diagnosis since patients with GCA 
are more likely to receive higher GC doses, thus tend to 
be monitored over a longer period of time.
COnClusIOn
Findings from this study underline the importance of 
screening for GC-induced DM in patients with GCA/
PMR in clinical practice1 5 and can also help inform 
dietary and lifestyle advice in patients taking GC for GCA 
or PMR. As well as limitations inherent to the meta-anal-
ysis itself, there remains considerable uncertainty in our 
estimate of the absolute risk of DM in PMR/GCA, since 
most published studies were not conducted with this as 
the primary aim. Furthermore, there is virtually no direct 
evidence as to which patients are at the greatest risk of 
DM, which would inform decisions as to how treatment 
should be individualised. We suggest that further research 
should analyse individual patient data within large data-
sets to generate clinically useful evidence to inform the 
next generation of clinical guidelines .
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